TG003: Selective Clk Family Kinase Inhibitor for Splicing Research

Executive Summary: TG003 is a nanomolar-range inhibitor of the Cdc2-like kinase (Clk) family, showing IC₅₀ values of 20 nM for Clk1, 200 nM for Clk2, >10 μM for Clk3, and 15 nM for Clk4, with additional inhibition of casein kinase 1 (CK1) (https://www.apexbt.com/tg003.html). It competitively inhibits ATP binding at Clk1 with a K_i of 0.01 μM and modulates alternative splicing by interfering with serine/arginine-rich (SR) protein phosphorylation (https://doi.org/10.1002/mco2.537). TG003 reversibly inhibits SR protein phosphorylation and alters nuclear speckle localization, impacting splicing factor SF2/ASF-mediated events. The compound is used in both cellular and animal models to study splicing regulation, platinum resistance in cancers, and exon-skipping therapies (https://doi.org/10.1002/mco2.537). APExBIO supplies TG003 as SKU B1431 for research use.

Biological Rationale

The Clk (Cdc2-like kinase) family consists of four serine/threonine protein kinases (Clk1–4) that regulate pre-mRNA processing via phosphorylation of SR proteins. These SR proteins are essential for splice site selection and alternative splicing, a process critical for gene expression diversity and disease pathogenesis. Clk1 and Clk2 are especially relevant in cancer research due to their overexpression in several tumor types and their role in resistance to platinum-based chemotherapies (Jiang et al., 2024). Inhibiting Clk activity can alter splicing decisions, potentially correcting aberrant mRNA processing events implicated in diseases such as Duchenne muscular dystrophy and various cancers. TG003 was developed to precisely target Clk kinases, enabling researchers to dissect the molecular mechanisms underlying splicing regulation and its therapeutic modulation [APExBIO].

Mechanism of Action of TG003

TG003 acts as a competitive inhibitor of ATP binding to Clk family kinases, particularly Clk1 (K_i = 0.01 μM) and Clk4 (IC₅₀ = 15 nM), with moderate activity against Clk2 (IC₅₀ = 200 nM) and poor inhibition of Clk3 (>10 μM). It also shows activity against CK1 [APExBIO]. TG003 blocks Clk-mediated phosphorylation of SR proteins including SF2/ASF, leading to the reversible inhibition of SR protein phosphorylation. This disruption results in altered nuclear speckle morphology and impaired alternative splicing, such as β-globin pre-mRNA splicing (Jiang et al., 2024). In vivo, TG003 modulates alternative splicing in murine tissues and can rescue splicing-related developmental phenotypes in Xenopus laevis embryos. The compound’s action is reversible upon washout, supporting its use in time-resolved mechanistic studies.

Evidence & Benchmarks

• TG003 inhibits Clk1-mediated phosphorylation of SF2/ASF with nanomolar potency (IC₅₀ = 20 nM) in biochemical assays (APExBIO product data).
• In cellular models, TG003 at 10 μM reversibly inhibits SR protein phosphorylation and alters nuclear speckle localization (https://doi.org/10.1002/mco2.537).
• TG003 modulates alternative splicing in vivo, rescuing Clk overexpression-induced defects in Xenopus laevis embryos (https://doi.org/10.1002/mco2.537).
• In murine models, subcutaneous administration at 30 mg/kg alters splice site selection in multiple tissues (https://doi.org/10.1002/mco2.537).
• TG003 promotes skipping of dystrophin exon 31 in Duchenne muscular dystrophy cell models, supporting its use in exon-skipping therapy research (APExBIO product data).
• CLK2 is upregulated in ovarian cancer, contributing to platinum resistance; Clk inhibition sensitizes cells to platinum-induced apoptosis (https://doi.org/10.1002/mco2.537).

This review extends prior coverage of TG003’s selectivity and translational value in splicing modulation by providing updated mechanistic and in vivo evidence (JIB-04: prior work focused on nanomolar activity; here, we elaborate on in vivo and disease model benchmarks).

Applications, Limits & Misconceptions

Applications:

• Alternative Splicing Modulation: Enables precise suppression of Clk1/2/4 activity for mechanistic and therapeutic studies in splicing regulation.
• Exon-Skipping Therapy: Demonstrated efficacy in promoting exon skipping in dystrophin transcripts, relevant for Duchenne muscular dystrophy models.
• Platinum Resistance Mechanisms: Facilitates study of Clk2’s role in DNA repair and apoptosis in ovarian cancer cells under platinum challenge (Jiang et al., 2024).
• Preclinical Cancer Models: Allows modulation of Clk-mediated pathways implicated in tumorigenesis and therapeutic resistance.

For a more focused discussion on Clk1 selectivity and advanced splicing models, see this article, which this review updates with new in vivo data and disease relevance.

Common Pitfalls or Misconceptions

• Non-selectivity for Clk3: TG003 shows poor potency for Clk3 (IC₅₀ >10 μM); it is not recommended for studies requiring Clk3 inhibition (APExBIO).
• Solubility Constraints: TG003 is insoluble in water; DMSO (≥12.45 mg/mL) or ethanol (≥14.67 mg/mL with ultrasonic treatment) are required for solution preparation.
• Short-term Stability: Solutions should be freshly prepared and used promptly; long-term storage of solutions is not recommended due to degradation risk.
• Cell Type Variability: Effective concentrations may vary by cell line or tissue; optimization is necessary for each experimental context.
• Non-clinical Use: TG003 is for research use only; it is not approved for clinical or therapeutic applications.

Workflow Integration & Parameters

TG003 (SKU B1431, supplied by APExBIO) is provided as a solid, water-insoluble compound. For in vitro use, dissolve in DMSO to at least 12.45 mg/mL; for ethanol, ultrasonic treatment increases solubility to ≥14.67 mg/mL. Store the solid form at -20°C. Prepare working solutions freshly before use. For cell-based assays, a final concentration of 10 μM in DMSO is standard. For animal studies, suspend TG003 at 30 mg/kg in a vehicle containing DMSO, Solutol, Tween-80, and saline, and administer via subcutaneous injection. Adjustments may be needed for specific experimental conditions due to batch or cell type variability. For real-world protocol and troubleshooting guidance, see this resource, which complements the present review with practical Q&A and optimization tips.

Conclusion & Outlook

TG003 is an essential research tool for dissecting Clk-mediated phosphorylation pathways and alternative splicing mechanisms. Its selectivity profile, validated activity in cellular and animal models, and robust performance in platinum resistance and exon-skipping research make it a preferred standard for mechanistic and translational studies. Ongoing research is expected to further define TG003’s utility in cancer biology and neuromuscular disease, with potential for supporting new therapeutic strategies targeting splicing regulation (Jiang et al., 2024). For the latest specifications and ordering information, consult the TG003 product page supplied by APExBIO.